⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2024

Supplementary Figure S5 from Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy

Stefano Scalera Biagio Ricciuti Daniele Marinelli Marco Mazzotta Laura Cipriani Giulia Bon Giulia Schiavoni Irene Terrenato Alessandro Di Federico Joao V. Alessi Maurizio Fanciulli Ludovica Ciuffreda Francesca De Nicola Frauke Goeman Giulio Caravagna Daniele Santini Ruggero De Maria Federico Cappuzzo Gennaro Ciliberto Mariam Jamal‐Hanjani Mark M. Awad Nicholas McGranahan Marcello Maugeri‐Saccà

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 5. KEAPness and the tumor immune microenvironment (TIME) in the TCGA NSCLC study

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Scalera et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efef68 https://doi.org/10.1158/1078-0432.27142039

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy2024
2Supplementary Figure S18 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy2024
3Supplementary Figure S4 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy2024
4Supplementary Figure S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy2024
5Supplementary Figure S8 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy2024